Woodline Partners reported beneficial ownership of 8,000,013 shares of Tango Therapeutics, Inc. common stock, representing 5.6% of the class. The filing states the percentage is calculated using 142,688,851 shares outstanding as of February 26, 2026. The ownership is held directly by Woodline Funds and Woodline Partners disclaims that this filing alone establishes beneficial ownership for Section 13 purposes.
Positive
None.
Negative
None.
Insights
Woodline holds a 5.6% stake (8.0M shares) in Tango Therapeutics.
Woodline Partners reports 8,000,013 shares and a 5.6% class stake based on 142,688,851 shares outstanding as of February 26, 2026. This places the Woodline Funds above the 5% reporting threshold that triggers public disclosure.
Future filings may show changes in position; changes would be visible through amended statements reporting updated share counts or percent ownership.
Filing is a Schedule 13G/A disclosure, not an admission of beneficial ownership.
The statement clarifies Woodline Partners is the investment adviser to named funds and includes a disclaimer that the filing should not be construed as admission of beneficial ownership under Section 13. The cover rows list sole voting and dispositive power for 8,000,013 shares.
Track amended filings for any shifts in voting/dispositive power or percent-of-class disclosures tied to updated outstanding share counts.
Key Figures
Reported shares owned:8,000,013 sharesPercent of class:5.6%Shares outstanding (base):142,688,851 shares
3 metrics
Reported shares owned8,000,013 sharesAmount set forth in Row 9 of the cover page and Item 4
Percent of class5.6%Calculated using 142,688,851 shares outstanding as of Feb 26, 2026
Shares outstanding (base)142,688,851 sharesUsed to calculate percent of class; as of Feb 26, 2026 per the Company's Form 10-K
Key Terms
Schedule 13G/A, sole dispositive power, beneficial ownership
3 terms
Schedule 13G/Aregulatory
"This statement is filed by Woodline Partners LP"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
sole dispositive powerregulatory
"Sole Dispositive Power 8,000,013.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
beneficial ownershipregulatory
"should not be construed as an admission that any of the foregoing persons"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Tango Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
87583X109
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
87583X109
1
Names of Reporting Persons
Woodline Partners LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
8,000,013.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
8,000,013.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
8,000,013.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.6 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Tango Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
201 Brookline Ave., Suite 901, Boston, MA 02215
Item 2.
(a)
Name of person filing:
This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP (together, the "Woodline Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Tango Therapeutics, Inc. (the "Company") directly held by the Woodline Funds.
The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)
Citizenship:
Woodline Partners is a Delaware limited partnership.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
87583X109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 142,688,851 shares of Common Stock outstanding as of February 26, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026.
(b)
Percent of class:
5.6%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Woodline Partners LP
Signature:
/s/ Erin Mullen
Name/Title:
Erin Mullen, General Counsel & Chief Compliance Officer
What stake does Woodline Partners report in Tango Therapeutics (TNGX)?
Woodline Partners reports ownership of 8,000,013 shares, or 5.6% of TNGX. The percent is calculated using 142,688,851 shares outstanding as of February 26, 2026, per Tango Therapeutics' 10-K filed March 5, 2026.
Does the 13G/A filing mean Woodline Partners is the beneficial owner?
No — the filing disclaims that it is not an admission of beneficial ownership. Woodline states it is the investment adviser to the Woodline Funds and includes language limiting Section 13 beneficial-owner characterization.
How were the ownership percentages calculated in the filing for TNGX?
The 5.6% figure uses 142,688,851 shares outstanding as of February 26, 2026. That outstanding share count is cited from Tango Therapeutics' Annual Report on Form 10-K filed March 5, 2026.
Who holds the reported shares for Woodline Partners in TNGX?
The shares are directly held by the Woodline Funds, for which Woodline Partners is investment adviser. The filing identifies Woodline Master Fund LP and Woodline Spire Master Fund LP as the holders represented by the reporting person.
What voting and disposition powers does Woodline report for TNGX shares?
Woodline reports sole voting power and sole dispositive power over 8,000,013 shares. The cover-page rows incorporated into Item 4 supply these figures as sole powers with no shared powers listed.
